Table 2.
Guidelines for CHC treatment according to Brazilian Ministry of Health.
| Conditions | Treatment | Duration |
|---|---|---|
| Genotype 1 | ||
| HCV monoinfected | Sofosbuvir + Simeprevir OR Sofosbuvir + Daclatasvir |
12 weeks |
| HCV monoinfected with Child-Pugh B/C OR previously treated by Telaprevir/Boceprevir OR HIV-HCV coinfection |
Sofosbuvir + Daclatasvir | 24 weeks |
| Genotype 2 | ||
| HCV monoinfected | Sofosbuvir + Ribavirin | 12 weeks |
| Genotype 3 | ||
| No contraindication for Peg-interferon | Sofosbuvir + Peg-interferon + Ribavirin | 12 weeks |
| Contraindication for Peg-interferon | Sofosbuvir + Daclatasvir | 12 weeks |
| Genotype 4 | ||
| No contraindication for Peg-interferon | Daclatasvir + Peg-interferon + Ribavirin | 24 weeks |
| Contraindication for Peg-interferon | Sofosbuvir + Daclatasvir | 12 weeks |
Source: Brazilian Ministry of Health [16].